The four retained variables—CAD, hypertension, renal insufficiency, and Alb levels—represent interconnected yet distinct pathophysiological pathways contributing to HF risk in elderly RRMM patients receiving carfilzomib therapy. This evidence concerns the gene ALB and coronary artery disorder.